Psoriasis Forum Journal
The National Psoriasis Foundation journal Psoriasis Forum is the only publication of its kind—dedicated to providing up-to-date and practical information to health care providers on the front line of psoriasis treatment.
Psoriasis Forum is sent to professional members of the Psoriasis Foundation. Become a professional member today.
Featured article:
Abstract
Background: Alefacept was the first biologic therapy approved for the treatment of chronic plaque psoriasis in Canada.
Objective: The AWARE study was an observational phase IV study whose main goal was to describe the outcomes of alefacept treatment in a broad population of Canadian psoriasis patients.
Methods: A total of 426 patients with chronic plaque psoriasis were enrolled from 37 clinics across Canada. Patients were treated with up to two courses of alefacept and followed for up to 60 weeks.
Results: The majority of patients had a moderate to marked response to alefacept treatment. Treatment with concomitant systemic therapy was discontinued or reduced in up to a third of subjects. Forty percent completed the entire follow-up period without receiving a second course of alefacept.
Conclusion: In routine clinical settings in Canada, alefacept is an effective and safe option for the treatment of a wide range of patients with psoriasis.
|
Also in this issue:
- Development of Multiple Viral Warts in a Patient Receiving the TNF-α Inhibitor Etanercept
- The Shared Decision Model: Who Should Decide What Is the Best Medical Treatment?
- The Appearance of Cutaneous Anaplastic Lymophoma in a Psoriasis Patient Taking Methotrexate
- Special Report: International Psoriasis Council Presents Top Psoriasis Research Articles for 2009
- Can Adalimumab Make a Smooth and Easy Transition From Cyclosporine a Reality? A Case Series of Successful Transitions
- A Practical Approach to the Use of Etanercept
- Narrow-band UVB: Is It Carcinogenic?
- Clinical Application of National Psoriasis Foundation Findings for Management of Psoriasis in Patients With Coexisting Hepatitis C Infection
- Efalizumab: What Went Wrong
Recent issues
Instructions for authors >>>
Manuscript preparation guidelines >>> (Word format)
Viewing and printing files in Adobe PDF format requires free Acrobat Reader software.
If you do not have this software installed on your computer, it is available at the
Adobe Web site.